Stay updated on ALKS 4230 in Advanced Melanoma Clinical Trial
Sign up to get notified when there's something new on the ALKS 4230 in Advanced Melanoma Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FcRG_RIVDpHqlBhUcgnIUBvf8WyI.uncropped.jpg&w=3840&q=75)
Latest updates to the ALKS 4230 in Advanced Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoChange DetectedThe website has been updated to version 2.10.0, introducing new features for viewing and comparing study record versions.SummaryDifference6%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.3%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision or update to the content of the webpage.SummaryDifference0.3%
- Check26 days agoChange DetectedThe study record for Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6) has been updated to reflect a change to Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6. This change occurred on July 1, 2024.SummaryDifference2%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.3%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content or details of the webpage.SummaryDifference0.3%
Stay in the know with updates to ALKS 4230 in Advanced Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALKS 4230 in Advanced Melanoma Clinical Trial page.